Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?
{{output}}
Purpose of review: This review examines the impact of glucagon-like peptide 1 receptor agonists (GLP-1RAs) on lipid profiles in individuals with type 2 diabetes mellitus and/or obesity, crucial for optimizing cardiovascular risk ... ...
